Drug Profile
Research programme: stem cell therapeutics - Cellular Dynamics International/National Eye Institute
Alternative Names: Retinal disease therapeutics - Cellular Dynamics International/National Eye InstituteLatest Information Update: 24 Jul 2023
Price :
$50
*
At a glance
- Originator National Eye Institute
- Developer Cellular Dynamics International; National Eye Institute
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Age-related macular degeneration
Most Recent Events
- 24 Jul 2023 Research programme: stem cell therapeutics is still in preclinical development for Age-related-macular-degeneration in USA (Intraocular)
- 28 Dec 2018 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Intraocular)
- 22 Jun 2016 Cellular Dynamics International establishes CRADA with the National Eye Institute for the development of Stem cell therapeutics in Ocular disorders